Mechanisms of selective autophagy
Mechanisms of selective autophagy
批准号:
10017261
负责人:
Maria F Czyzyk-Krzeska
金额:
$32.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-12 至 2023-08-31
关键词:
Adaptor Signaling ProteinAmino AcidsAutophagocytosisAutophagosomeBindingBinding SitesC-terminalCellsChromosomesClear cell renal cell carcinomaCleaved cellComplexCytokinesisDataDigestionEventExcisionGenesGlycineHumanHydroxylationHypoxiaKidneyLaboratoriesLightLipidsMAP1 Microtubule-Associated ProteinMalignant NeoplasmsMediatingMediator of activation proteinMembraneMembrane MicrodomainsMetabolismModelingMolecularOncogenicPathologyPathway interactionsPeptidesPrimatesProcessProlineProteinsRegulationRenal carcinomaRoleSorting - Cell MovementStructureTSG101 geneTumor SuppressionTumor Suppressor GenesTumor Suppressor ProteinsVHL geneWorkangiogenesiscancer cellcancer therapycaveolin 1cholesterol-binding proteingene functiongene repressioninsightmembernovelprogramsprotein complexreceptorrecruitstemtheoriestranscription factortumortumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In this proposal we investigate mechanism of selective autophagy in a novel, noncanonical pathway which has
tumor suppressing activity in renal cancer. Autophagy is a tightly regulated process of self-digestion, which in
cancer can have both tumor suppressing and oncogenic activities. Formation of an autophagosome requires
microtubule associated protein 1 light chains A, B and C (MAP1LC3A, B, C referred to as LC3A, B and C). LC3s
bind with cargo receptors through the LC3C-interacting regions (LIR) motifs on the receptors. Clear cell renal
cell carcinoma (ccRCC) is the most frequent renal cancer characterized by the loss the von Hippel-Lindau gene
(VHL). Loss of VHL function leads to activation of Hypoxia Inducible Transcription Factors (HIF) and changes in
angiogenesis and metabolism. Our laboratory discovered that VHL regulates autophagy. VHL inhibits LC3B
autophagy, which is oncogenic in ccRCC. In contrast, VHL induces tumor suppressing, LC3C autophagy in a
mechanism that involves removal of transcription repression by HIF. LC3C is an evolutionary late gene, present
only in higher primates and humans that evolved into multifaceted autophagic regulator, more complicated as
compared to LC3B/A. It maintains binding site for the canonical LIRs, similar to other LC3s, but it gained a new
binding site for LC3C-specific LIR, CLIR, and a highly conserved C-terminal, 20 amino acid peptide, cleaved in
the process of glycine lipidation. Our preliminary results show that LC3C autophagy requires novel non-canonical
pre- and -initiation complexes, which include ULK3, BECN1, UVRAG and PIK3C2A. We identified two direct
targets selectively degraded by LC3C autophagy: (i) Postdivision Midbody Rings (PDMBs), remnants of midbody
structures created during cytokinesis. PDMB accumulation in cancer cells promotes stem-like state and cancer
progression. (ii) Caveolin 1(CAV1), a lipid raft cholesterol-binding protein. We found that LC3C-dependent
degradation of the cargo requires C-terminal peptide on LC3C and a protein complex that includes adapter
proteins, TSG101 and CHMP2B. Surprisingly, VHL interacts with the core autophagy apparatus in an LC3C-
dependent manner, an indication that it directly serves in the formation of LC3C autophagosomes. In Aim 1, we
will determine activity of the LC3C preinitiation, initiation, and adapter complexes. We hypothesize that LC3C
autophagy is regulated by distinctive and selective mediators, as compared to LC3B, of the pre- and initiation
complexes and TSG101 anchors LC3C to the selective cargo. In Aim 2 we will determine the direct role of VHL
in regulation of LC3C autophagy. We propose that VHL anchors at the LC3C regulatory complex through the
hydroxylated proline in the C-terminal peptide and is necessary for the association with the core autophagic
proteins. In Aim 3 we will determine the role of unique structures of LC3C in the selective degradation of cargo
by the non-canonical pathway and in tumor suppressing activity of LC3C. We hypothesize that this process
requires the evolutionary recent C-terminal peptide.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Metabolic effects of cooper in renal cancer
-
批准号:10792732
-
项目类别:
-
资助金额:$57.85万
-
财政年份:2023
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Mechanisms of selective autophagy
-
批准号:9765722
-
项目类别:
-
资助金额:$31.47万
-
财政年份:2019
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Mechanisms of selective autophagy
-
批准号:10240490
-
项目类别:
-
资助金额:$32.1万
-
财政年份:2019
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor suppressing pathways in renal cancer
-
批准号:10426280
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor Suppressing Pathways in Renal Cancer
-
批准号:8398967
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor suppressing pathways in renal cancer
-
批准号:10252173
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor Suppressing Pathways in Renal Cancer
-
批准号:8696822
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor Suppressing Pathways in Renal Cancer
-
批准号:8305417
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor Suppressing Pathways in Kidney Cancer
-
批准号:10166749
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor Suppressing Pathways in Renal Cancer
-
批准号:8140551
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Tumor Suppressing Pathways in Kidney Cancer
-
批准号:9326809
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Molecular Mechanisms of Renal Cancer
-
批准号:8448354
-
项目类别:
-
资助金额:$29.14万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Role of ubiquitylation in renal cancer
-
批准号:8516794
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Role of ubiquitylation in renal cancer
-
批准号:7666796
-
项目类别:
-
资助金额:$29.64万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Role of ubiquitylation in renal cancer
-
批准号:7894585
-
项目类别:
-
资助金额:$29.64万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Molecular Mechanisms of Renal Cancer
-
批准号:8611902
-
项目类别:
-
资助金额:$28.34万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Role of ubiquitylation in renal cancer
-
批准号:7491622
-
项目类别:
-
资助金额:$29.64万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Molecular Mechanisms of Renal Cancer
-
批准号:8827261
-
项目类别:
-
资助金额:$29.14万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Role of ubiquitylation in renal cancer
-
批准号:7262804
-
项目类别:
-
资助金额:$29.64万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
Role of ubiquitylation in renal cancer
-
批准号:8106369
-
项目类别:
-
资助金额:$28.75万
-
财政年份:2007
-
负责人:Maria F Czyzyk-Krzeska
-
依托单位:
海外基金